Multi-dose Vials

• Cyclic nonapeptide hormone with characteristic Cys1-Cys6 disulfide bridge, synthesized by Nobel laureate Vincent du Vigneaud (1954)
• OXTR agonist activating Gq/11-PLC-IP3/DAG cascade; modulates social cognition, stress axis, metabolism, and cardiovascular function
• Validated in ~25,000 publications spanning social neuroscience, reproductive physiology, psychiatry, metabolic medicine, and cardiology

• FDA-Approved Melanocortin Agonist: Cyclic heptapeptide MC3R/MC4R agonist, approved June 2019 (Vyleesi) for premenopausal HSDD, 100+ publications, first melanocortin therapeutic for sexual function
• CNS Mechanism: Crosses blood-brain barrier, activates hypothalamic MC4R in mPOA triggering dopamine release, melanocortin-dopamine integration, mesolimbic reward pathway modulation
• Clinical Development: 43 completed trials with 3,500+ subjects, Phase 3 RECONNECT (n=1,267) showed +0.35 desire improvement, 58% vs 36% responder rates, well-characterized safety profile

Reconstitution Solution (10ml)

• Profile: Sterile bacteriostatic water for peptide reconstitution
• Quality: >=95% Purity (HPLC Verified)

• First-in-Class Triple Agonist: 39 aa peptide simultaneously activating GIPR (EC₅₀ 0.0643 nM), GLP-1R (EC₅₀ 0.775 nM), GCGR (EC₅₀ 5.79 nM), GIP backbone with Aib/C20 fatty diacid, t½ 6 days, once-weekly
• Superior Efficacy: Phase 2 obesity 24.2% weight loss at 48 weeks (12 mg), MASLD 82.4% liver fat reduction, T2D HbA1c -2.02%, 100+ publications, 100% ≥5% weight loss responders
• Clinical Development: Phase 3 TRIUMPH program (5,800+ participants), TRIUMPH-4 showed 26.4-28.7% weight loss at 68 weeks, TRANSCEND cardiovascular outcomes program, dose-dependent GI AEs

• Synthetic Tuftsin Analogue: Heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed Russian Academy of Sciences, tuftsin core + Pro-Gly-Pro extension for metabolic stability, 20+ years research
• Multi-Modal Mechanism: Positive allosteric modulator of GABA-A receptors, upregulates BDNF (hippocampus/cortex), inhibits enkephalinase (IC50 15 μM), modulates monoamines, no tolerance/dependence
• Clinical Status: Russian FDA approved 2009 for GAD/neurasthenia (intranasal 0.15%), RCT showed efficacy equal to medazepam with additional nootropic effects, no sedation/amnesia unlike benzodiazepines

• ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
• Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
• Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile